Mammalian target of rapamycin: Biological function and target for novel anticancer agents

American Journal of Health-System Pharmacy

Volumn 67, Issue 24, 2010, Pages 2095-2106

  Borders, Emily B ^a   Bivona, Cory ^b   Medina, Patrick J ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b UNIVERSITY OF KANSAS HOSPITAL   (United States)

Author keywords

Antineoplastic agents; Everolimus; Mechanism of action; Neoplasms; Resistance; Site of action; Temsirolimus; Toxicity

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ALPHA2A INTERFERON; CISPLATIN; ERYTHROMYCIN; EVEROLIMUS; KETOCONAZOLE; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OSI 027; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RIDAFOROLIMUS; RIFAMPICIN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VERAPAMIL; XL 765; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MTOR PROTEIN, HUMAN; RAPAMYCIN;

ADVANCED CANCER; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CARCINOGENESIS; COUGHING; DISEASE MARKER; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; DYSPNEA; ENDOMETRIUM CANCER; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; KIDNEY CARCINOMA; MUCOSA INFLAMMATION; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MONITORING; DRUG RESISTANCE; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79952495236     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100020     Document Type: Review

References (61)

1. Polhmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer. 2009; 15:7479-91.
2. Rapamune (sirolimus) package insert. Philadelphia, PA: Wyeth Pharmaceuticals; 2010 Sep.
3. Liu P, Cheng H, Roberts TM et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature. 2009; 8:627-44.
4. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 124:471-84.
5. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27:2278-87.
6. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nature. 2006; 6:729-34.
7. Bai X, Jiang Y. Key factors in mTOR regulation. Cell Mol Life Sci. 2010; 67:239-53.
8. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008; 1:27-36.
9. Rosner M, Hengstschlager M. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet. 2008; 17:2934-48.
10. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004; 22:2954-63. (Pubitemid 41079915)
11. Mak BC, Yeung RS. The tuberous sclerosis complex genes in tumor development. Cancer Invest. 2004; 22:588-603. (Pubitemid 39506880)
12. Pantuck AJ, Seligson DB, Klatte T et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007; 109:2257-67. (Pubitemid 46801555)
13. Castellvi J, Garcia A, Rojo F et al. 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer. 2006; 107:1801-11. (Pubitemid 44582949)
14. Guertin DA, Sabitini DM. The pharmacology of mTOR inhibition. Sci Signal. 2009; 2:pe24.
15. Torisel (temsirolimus) package insert. Philadelphia: Wyeth Pharmaceuticals; 2008 Aug.
16. Afinitor (everolimus) package insert. East Hanover, NJ: Novartis Pharmaceuticals; 2009 Mar.
17. Yuan R, Kay A, Berg WJ et al. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009; 2:45.
18. Furic L, Livingstone A, Dowling RJ et al. Targeting mtor-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses. Curr Oncol. 2009; 16:59-61.
19. Nowak P, Cole DC, Brooijmans N et al. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase. J Med Chem. 2009; 52:7081-9.
20. Konstantinidou G, Bey EA, Rabellino A et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 2009; 69:7644-52.
21. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6:117-27. (Pubitemid 39485684)
22. Andre F, Campone M, Hurvitz SA et al. Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol. 2008; 26(suppl):abstract 1003.
23. Miller TW, Forbes JT, Shah C et al. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res. 2009; 15:7266-76.
24. Soria JC, Shepherd FA, Douillard JY et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol. 2009; 20:1674-81.
25. Kris MG, Riley GJ, Azzoli CG et al. Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: a phase II trial. J Clin Oncol. 2007; 25(suppl):7575.
26. Beeram M, Tan QT, Tekmal RR et al. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol. 2007; 18:1323-8. (Pubitemid 47305004)
27. Chow L, Sun Y, Jassem J et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2006; 100(suppl):abstract 6091.
28. Awada A, Cardoso F, Fontaine C et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer. 2008; 44:84-91. (Pubitemid 350256937)
29. Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009; 27:2630-7.
30. NCT00863655: Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole (BOLERO-2). http:/clinicaltrials.gov/ct2/show/NCT00863655?term= nct00863655&rank=1 (accessed 2010 Nov 2).
31. Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2009; 28:69-76.
32. Theodoropoulou M, Zhang J, Laupheimer S et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2006; 66:1576-82. (Pubitemid 43259940)
33. Beuvink I, Boulay A, Fumagalli S et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005; 120:747-59. (Pubitemid 40568794)
34. Bae-Jump VL, Zhou C, Boggess JF et al. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer. 2009; 115:3887-96.
35. Mondesire WH, Jian W, Zhang H et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004; 10:7031-42. (Pubitemid 39383055)
36. Akcakanat A, Sahin A, Shayne AN et al. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer. 2008; 112:2352-8.
37. Figlin RA, de Souza P, McDermott D et al. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferonalpha. Cancer. 2009; 115:3651-60.
38. Cho D, Signoretti S, Dabora S et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007; 5:379-85. (Pubitemid 47584475)
39. National Comprehensive Cancer Network. NCCN clinical practice guidelines in Oncology: Kidney cancer (v2.2010). www.nccn.org/professionals/physician-gls/ f-guidelines.asp (accessed 2010 Nov 2).
40. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356:2271-81. (Pubitemid 46849157)
41. Atkins M, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004; 22:909-18. (Pubitemid 41103603)
42. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17:2530-40. (Pubitemid 29368255)
43. Motzer RJ, Murphy BA, Bacik J et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20:289-96. (Pubitemid 34032623)
44. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372:449-56.
45. Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009; 27:3822-9.
46. Smith SM, Pro B, Cisneros A et al. Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes. J Clin Oncol. 2008; 26(suppl):457S.
47. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nature. 2006; 5:671-88. (Pubitemid 44151605)
48. Kanamori Y, Kigawa J, Itamochi H et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res. 2001; 7:892-5. (Pubitemid 32708726)
49. Slomovitz BM, Lu KH, Johnston T et al. A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC). J Clin Oncol. 2008; 26(suppl):abstract 5502.
50. Galanis E, Buckner IC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005; 23:5294-304. (Pubitemid 46206983)
51. Von Wichert G, Jehle PM, Hoeflich A et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 2000; 60:4573-81. (Pubitemid 32103642)
52. Temsirolimus i.v. monograph. In: McEvoy G, ed. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists; 2009.
53. O'Donnell A, Faivre S, Burris HA III et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008; 26:1588-95.
54. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004; 22:2236-47.
55. Sankhala K, Mita A, Kelly K et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 2009; 4:135-42.
56. Duran I, Siu LL, Oza AM et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer. 2006; 42:1875-80. (Pubitemid 44149096)
57. Morelon E, Stern M, Israël-Biet D et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation. 2001; 72:787-90. (Pubitemid 32879846)
58. Pham PT, Pham PC, Danovitch GM et al. Sirolimus-associated pulmonary toxicity. Transplantation. 2004; 77:1215-20. (Pubitemid 38580300)
59. Hutson TE, Figlin RA, Kuhn JG et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008; 13:1084-96.
60. Hoyle M, Green C, Thompson-Coon J et al. Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. Value Health. 2009; 13:61-8.
61. Cauley DH. Newly approved mTOR inhibitors for the treatment of metastatic renal cell carcinoma. US Pharm. 2009; 34:HS-20-6.